DaVita (DVA)
(Delayed Data from NYSE)
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$161.97 USD
+1.87 (1.17%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value C Growth D Momentum A VGM
Zacks News
5 Stocks Trading Near 52-Week High With More Upside Potential
by Vasundhara Sawalka
Investors target stocks that have lately been on a bull run. Stocks like HAS, EAT, DVA, LDOS and ALL are seeing price strength and have a high chance of carrying the momentum forward.
4 Must-Buy Momentum Stocks Banking on the Driehaus Strategy
by Tirthankar Chakraborty
DaVita (DVA), Minerals Technologies (MTX), Alphabet (GOOGL) and Garmin (GRMN) have been selected as the momentum picks for the day using the Driehaus strategy.
Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice
by Zacks Equity Research
Does DaVita HealthCare (DVA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Industry Outlook Highlights DaVita, Encompass Health, Option Care Health and The Pennant Group
by Zacks Equity Research
DaVita, Encompass Health, Option Care Health and The Pennant Group have been highlighted in this Industry Outlook article.
4 Stocks to Buy in a Thriving Outpatient Home Health Industry
by Debanjana Dey
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, EHC, OPCH and PNTG are well-poised to gain.
The Zacks Analyst Blog Highlights DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant
by Zacks Equity Research
DaVita, Option Care Health, Addus HomeCare, Encompass Health and The Pennant are included in this Analyst Blog.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are Medical Stocks Lagging DaVita (DVA) This Year?
by Zacks Equity Research
Here is how DaVita HealthCare (DVA) and Alcon (ALC) have performed compared to their sector so far this year.
Top 5 Outpatient and Home Healthcare Stocks for Solid Returns
by Nalak Das
We have narrowed our search to outpatient and home healthcare stocks that have strong growth potential for 2024. These are: DVA, ADUS, OPCH, EHC, PNTG.
Is DaVita (DVA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DaVita HealthCare (DVA) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
DaVita Inc. (DVA) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
DaVita HealthCare (DVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks for May 6th
by Zacks Equity Research
ROOT, SMCI, PPC, DFH and DVA have been added to the Zacks Rank #1 (Strong Buy) List on May 6, 2024.
Best Value Stocks to Buy for May 6th
by Zacks Equity Research
DFH, DVA and BDC made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 6, 2024.
DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
DaVita's (DVA) robust segmental revenues drive its first-quarter performance.
DaVita HealthCare (DVA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 21.43% and 2.01%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
by Zacks Equity Research
Improvement in revenue per treatment and cost-saving initiatives are likely to have boosted DaVita's (DVA) top line in the first quarter.
What's in Store for These 5 Medical Device Stocks in Q1 Earnings?
by Zacks Equity Research
Here is a sneak peek into how five medical device stocks, BDX, BAX, XRAY, CAH and DVA, might fare in their quarterly results slated to be released tomorrow.
DaVita HealthCare (DVA) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
DaVita HealthCare (DVA) concluded the recent trading session at $132.77, signifying a +0.02% move from its prior day's close.
Amedisys (AMED) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 1.98% and 1.21%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Philips' (PHG) Zenition 30 to Boost Image-Guided Surgeries
by Zacks Equity Research
Philips (PHG) announces the FDA clearance for its Zenition 30 mobile C-arm, which is intended to aid in image-guided procedures at a relatively affordable cost.
Is Trending Stock DaVita Inc. (DVA) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to DaVita HealthCare (DVA). This makes it worthwhile to examine what the stock has in store.
Neogen (NEOG) Inks Genomics Deal to Aid in Food Tracing
by Zacks Equity Research
Neogen (NEOG) announces a genomics relationship with Performance Food Group to trace food products back to their origin using PathProven food trace technology.
DaVita HealthCare (DVA) Advances While Market Declines: Some Information for Investors
by Zacks Equity Research
DaVita HealthCare (DVA) closed at $127.82 in the latest trading session, marking a +1.36% move from the prior day.
Reasons Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.